The staples are Ossio’s fifth product family and will provide solutions for midfoot and hindfoot procedures.
The staples are made from Ossio’s proprietary bone regeneration technology that leaves no permanent hardware behind.
Ossio’s staples received FDA 510(k) clearance in January 2022 for fixation in hand or foot fractures.
OrthoCarolina surgeon Samuel Ford, MD, and Rothman Orthopedic Institute surgeon Selene Parekh, MD, were among the first to use the staples commercially.
“I love the fact that there is no metal blocking the view of the fusion site, and the compression and stability achieved just from the one staple was better than what I typically see for metal staples. By using a non-permanent implant, we restore patient mobility and stability through a natural healing process and patients avoid long-term implant prominence,” Dr. Parekh said in a Feb. 7 press release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
